Vivus posts shortfall in Qsymia sales; Boehringer, Lilly unveil diabetes education push for doctors;

@FiercePharma: India's own drugmakers are turned off their home market by gov't policy. For them, it's price caps. More | Follow @FiercePharma

@EricPFierce: Rapidly growing Sagent takes control of FDA approved China plant that is ready to produce products. Article | Follow @EricPFierce

> Vivus ($VVUS) reported weaker-than-expected sales of its weight-loss pill Qsymia for the first quarter, with product revenue at $4.1 million. Report

> Only half of people infected with hepatitis C in the U.S. actually get proper testing to determine whether they need treatment, public health officials say. Report

> Boehringer Ingelheim and Eli Lilly ($LLY) have developed a joint education campaign for doctors to better illuminate the mechanisms behind one of their Type 2 diabetes drugs. Report

> Bristol-Myers Squibb's ($BMY) HIV fighter Sustiva won a new indication from FDA for use in pediatric patients from three months to three years of age. Report

> Private-label over-the-counter drugmaker Perrigo reported record quarterly revenue with $920 million in net sales, up 18% year over year. Report

> Generics maker Akorn posted a 43% increase in revenue to $73.8 million for the first quarter, falling short of analysts' estimates of $74.1 million; the company also lowered its forecast on a slower-than-expected Superstorm Sandy recovery. Report

Medical Device News

@FierceMedDev: FDA warns of criminals hocking stolen Covidien stapler reloads. More | Follow @FierceMedDev

@MarkHFierce: Biotronik won FDA approval for ICD/CRT-D devices, keeping it in the global race to unveil new products in the space. Story | Follow @MarkHFierce

 @DamianFierce: Stan Musial rises from the grave and takes a job at a specialty pharma outfit. Amazing, really. Release | Follow @DamianFierce

> ArthroCare's Q1 numbers come in flat. Article

> Good Start Genetics raises $28M for carrier Dx. News

Biotech News

@FierceBiotech: Nimbus Discovery announced agreement with Shire focused on small molecule treatments for rare genetic diseases. Release | Follow @FierceBiotech

@JohnCFierce: Painful to watch Vivus ($VVUS) scratching out sales for its weight drug. It's not built to market a drug like that. More | Follow @JohnCFierce

@RyanMFierce: Pfizer opts to keep running Accelrys software in its labs. Article | Follow @RyanMFierce

> Genomics, Biotechnology's Oldest Next Big Thing. Industry Voices

> Startup biotech charges into PhII with $23M bankroll for rare disease drugs. Article

> Takeda beefs up new vaccines arm with $250M bolt-on buyout of Inviragen. News

Drug Delivery News

@MichaelGFierce: Frederick National Lab leads nanotech boom with cancer drug delivery. Report | Follow @MichaelGFierce

> 'Buckyball' capsule lets researchers steer drugs to target. Article

> Math model could choose most effective drug delivery nanoparticle. Story

> Langer's Kala touts positive results for topical wet AMD treatment. Report

> 'Smart' insulin nanoparticle controls blood sugar levels for up to 10 days. More

And Finally... A quick uptick in deaths and infections from a SARS-like virus in Saudi Arabia has officials worried. Report

Suggested Articles

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

Patients receiving Bavencio actually did worse than those who got placebo, increasing the risk of death by 31%.

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.